

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:)	
)	
Takanori MATSUO et al.)	Group Art Unit: 1644
)	
Application No.: 10/534,486)	Examiner: Gerald R. EWOLDT
)	
Filed: May 11, 2005)	
)	Confirmation No.: 7810
For: PROPHYLACTIC OR)	
THERAPEUTIC SUBSTANCE)	
FOR DIABETES OR A RENAL)	
DISEASE ASSOCIATED WITH)	
TSC-22 AND SCREENING)	
METHOD THEREOF)	

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

INFORMATION DISCLOSURE STATEMENT UNDER 37 C.F.R. § 1.97(c)

Pursuant to 37 C.F.R. §§ 1.56 and 1.97(c), Applicants bring to the attention of the Office the documents on the attached listing. This Information Disclosure Statement is being filed after the events recited in Section 1.97(b) but, to the undersigned's knowledge, before the mailing date of either a Final action, Quayle action, or a Notice of Allowance. Under the provisions of 37 C.F.R. § 1.97(c), this Information Disclosure Statement is accompanied by a fee of \$180.00 as specified by Section 1.17(p).

A copy of the U.S. patent document is not enclosed. Copies of the listed non-patent literature documents are attached. We further provide a full translation of the previously submitted foreign patent document JP 11-152228, and a legible copy of the previously submitted non-patent document Rae et al. (2000) published in the

International Journal of Cancer, both of which were submitted in an Information Disclosure Statement filed on May 11, 2005.

Applicants respectfully request that the Office consider the listed documents and indicate that they were considered by making appropriate notations on the attached form.

This submission does not represent that a search has been made or that no better art exists and does not constitute an admission that each or all of the listed documents are material or constitute "prior art." If the Office applies any of the documents as prior art against any claims in the application and Applicants determine that the cited document(s) do not constitute "prior art" under United States law, Applicants reserve the right to present to the Office the relevant facts and law regarding the appropriate status of such documents.


Applicants further reserve the right to take appropriate action to establish the patentability of the disclosed invention over the listed documents, should one or more of the documents be applied against the claims of the present application.

If there is any additional fee due in connection with the filing of this Statement, please charge the fee to Deposit Account No. 06-0916.

Respectfully submitted,

FINNEGAN, HENDERSON, FARABOW,
GARRETT & DUNNER, L.L.P.

Dated: October 29, 2008

By: 
Yuko Soneoka
Reg. No. 60,018